InMed Pharmaceuticals Inc.INMNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank77
5Y CAGR+75.4%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+75.4%/yr
Long-term compound
Percentile
P77
Within normal range
vs 5Y Ago
16.6x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 48.78% |
| Q3 2025 | 278.81% |
| Q2 2025 | -83.12% |
| Q1 2025 | -14.21% |
| Q4 2024 | 37.50% |
| Q3 2024 | -36.07% |
| Q2 2024 | 83.69% |
| Q1 2024 | 7.70% |
| Q4 2023 | -52.81% |
| Q3 2023 | 56.37% |
| Q2 2023 | -5.92% |
| Q1 2023 | -23.80% |
| Q4 2022 | -39.46% |
| Q3 2022 | 26.88% |
| Q2 2022 | -14.42% |
| Q1 2022 | -45.34% |
| Q4 2021 | 115.13% |
| Q3 2021 | -13.12% |
| Q2 2021 | -3.17% |
| Q1 2021 | 88.99% |
| Q4 2020 | 2.94% |
| Q3 2020 | -30.64% |
| Q2 2020 | 3.04% |
| Q1 2020 | -20.66% |
| Q4 2019 | -18.10% |
| Q3 2019 | 2.92% |
| Q2 2019 | 57.52% |
| Q1 2019 | 74.07% |
| Q4 2018 | 43.23% |
| Q3 2018 | 15.63% |
| Q2 2018 | -2.28% |
| Q1 2018 | 29.13% |
| Q4 2017 | 9.43% |
| Q3 2017 | 2.07% |
| Q2 2017 | 127.16% |
| Q1 2017 | 3.93% |
| Q4 2016 | 606.44% |
| Q3 2016 | -59.95% |
| Q2 2016 | -10.96% |
| Q1 2016 | -58.61% |